Company news
Cardiol Therapeutics Inc. Class A (TSX:CRDL) news
Cardiol Therapeutics Inc. Class A news releases on 6ix. Latest, Jun 3, 2024: Sector Spotlight: Orphan Drug Developers With Significant Upside
Press releases — page 2
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 3, 2024
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
May 14, 2024
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
April 2, 2024
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
January 24, 2024
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
January 9, 2024
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
December 5, 2023
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
November 16, 2023
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 1, 2023
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
October 20, 2023
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
October 11, 2023
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
September 26, 2023
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
August 9, 2023
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
June 29, 2023
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
June 27, 2023
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
March 29, 2023
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
March 7, 2023
Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis
January 17, 2023
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis
January 17, 2023
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis
December 16, 2022
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis
December 12, 2022
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis
November 7, 2022
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
October 25, 2022
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
October 3, 2022
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis
August 3, 2022
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
June 29, 2022
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT
June 27, 2022
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
June 9, 2022
Market Movers. Today's Top Stock Picks For New & Trending Opportunities
May 27, 2022
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors
May 19, 2022
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis
May 17, 2022
Cardiol Therapeutics Announces Year-End 2021 Update on Operations
March 24, 2022
Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit
March 22, 2022
Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors
March 15, 2022
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial
March 1, 2022
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
January 19, 2022
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
November 5, 2021
Cardiol Therapeutics Announces Pricing of Public Offering of Units
November 3, 2021
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units
November 2, 2021
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
October 25, 2021
Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada
October 18, 2021
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 16, 2021
Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020
September 10, 2021
Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors
September 7, 2021
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
August 24, 2021